Inhibitory DNA ligands to platelet-derived growth factor
Human iliac artery endothelial cells express both genes encoding the chains of platelet-derived growth factor
(PDGF) and synthesize PDGF-like mitogens.
4-8) Recently, additional new markers including CD44, platelet-derived growth factor
receptor [alpha] (PDGFR-[alpha]), and cyclooxygenase 2 (COX-2) have been proposed as potential prognostic indicators.
Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor
in mononuclear phagocytes stimulates growth of hypoxic endothelial cells.
Simon MP, Pedeutour F, Sirvent N, et al: Deregulation of the platelet-derived growth factor
B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.
All Augment([R]) branded products are based upon recombinant human platelet-derived growth factor
(rhPDGF-BB), which is a bio-engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration.
Sutent is an oral multi-kinase inhibitor that works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer, including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor
The company stated that AR-13154 targets Rho Kinase, Janus Kinase 2, and platelet-derived growth factor
PRF releases a number of growth factors namely, transforming growth factor [beta]-1 (TGF-beta-1), vascular endothelial growth factor (VEGF), platelet-derived growth factor
[alpha][beta] (PDGF-AB) and thrombospondin-1 (TSP-1) during 7 days.
Significance of the platelet-derived growth factor
in periodontal tissue regeneration.
Platelets release several growth factors, such as platelet-derived growth factor
, transforming growth factor-B, and vascular endothelial and epithelial growth factors.
The Food and Drug Administration announced that the warning had been added to the label of becaplermin (Regranex), a recombinant human platelet-derived growth factor
that was approved in 1997.
Johnson & Johnson had already been monitoring a potential cancer link, as becaplermin, a recombinant form of human platelet-derived growth factor
, inherently had the potential to accelerate disease.